Adam Lauver , PhD
Biography
I am a pharmacologist at Michigan State University, where I lead research focused on cardiovascular pharmacology, drug discovery, and pharmacokinetics. My work explores the vascular effects of antiplatelet therapies, particularly clopidogrel, and investigates novel drug candidates for cardiovascular and infectious diseases. As director of the MSU Certara Center of Excellence, I integrate computational modeling with experimental pharmacology to optimize drug development. Through industry collaborations and NIH-funded projects, my research advances translational pharmacology with the goal of improving therapeutic outcomes.
Education
Postdoctoral, Pharmacology, University of Michigan, 2007
Ph.D., Pharmacology, University of Michigan, 2002
B.S., , Pennsylvania State University, 1997
Employment
Associate Professor, Michigan State University, East Lansing, 2016 - Present
Research Assistant Professor, University of Michigan, Ann Arbor, 2011 - 2016
, Bristol-Myers Squibb Co, Moreton, 2001 - 2002
Publications
Non-cytotoxic, iodinated poly(ethylene oxide) (PEO) block-co-polymer contrast agents for computed tomography (CT) imaging Journal of Materials Chemistry B (2026)
Perivascular Adipocytes’ Adipogenesis Is Defined by Their Anatomical Location in the Descending Thoracic Aorta Cells (2025)
The “One‐Step” approach for QT analysis increases the sensitivity of nonclinical QTc analysis Clinical and Translational Science (2023)
Improving corrected QT; Why individual correction is not enough Journal of Pharmacological and Toxicological Methods (2022)
Pleiotropic effects of clopidogrel Purinergic Signalling (2022)
QT Ratio: A simple solution to individual QT correction Journal of Pharmacological and Toxicological Methods (2022)
Clopidogrel treatment inhibits P2Y2-Mediated constriction in the rabbit middle cerebral artery European Journal of Pharmacology (2021)
Clopidogrel treatment inhibits P2Y2-Mediated constriction in the rabbit middle cerebral artery European Journal of Pharmacology (2021)
DT‐678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y12 antagonists Pharmacology Research & Perspectives (2019)
DT-678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y12 antagonists Pharmacology Research and Perspectives (2019)
